Related Experiment Video

Updated: Jun 14, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Clinical and genetic risk factors for moderate hyperbilirubinemia in Brazilian newborn infants

M A Mezzacappa1, F P Facchini, A C Pinto

  • 1Division of Neonatology, Department of Pediatrics, School of Medical Sciences, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.

Journal of Perinatology : Official Journal of the California Perinatal Association
|April 9, 2010
PubMed

Insights

Clinical factors like premature birth are key predictors of newborn jaundice. Genetic factors, including glucose-6-phosphate dehydrogenase deficiency and UGT1A1 gene variations, were not found to increase the risk of moderate hyperbilirubinemia in this Brazilian cohort.

Area of Science:

  • Neonatal Medicine
  • Clinical Genetics
  • Pediatric Hematology

Background:

  • Moderate hyperbilirubinemia is a common condition in newborns.
  • Identifying risk factors is crucial for timely intervention and preventing complications.
  • Genetic predispositions, such as G6PD deficiency and UGT1A1 polymorphisms, are potential contributors to hyperbilirubinemia.

Purpose of the Study:

  • To investigate clinical and genetic risk factors for moderate hyperbilirubinemia in Brazilian newborns.
  • To determine the association between G6PD deficiency and UGT1A1 gene polymorphisms and elevated bilirubin levels.
  • To identify independent clinical predictors of hyperbilirubinemia.

Main Methods:

  • A cohort of 608 Brazilian newborns was studied.
  • Univariate and multivariate regression analyses were used to assess risk.
  • Total bilirubin levels were monitored, and genetic factors (G6PD deficiency, UGT1A1 polymorphisms) were analyzed.

Main Results:

  • Gestational age less than 38 weeks and bilirubin levels above the 40th percentile were significant clinical predictors.
  • The African variant of G6PD deficiency and specific UGT1A1 polymorphisms were not identified as risk factors.
  • The co-occurrence of G6PD deficiency and UGT1A1 polymorphisms was rare and not associated with increased risk.

Conclusions:

  • In this population, G6PD deficiency and UGT1A1 gene promoter polymorphisms do not appear to be significant risk factors for moderate hyperbilirubinemia.
  • Clinical factors, particularly gestational age, are more influential predictors.
  • The relevance of genetic factors in hyperbilirubinemia may differ across diverse ethnic and geographic populations.
Abstract

More Related Videos

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats04:12

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

Biochemical Measurement of Neonatal Hypoxia13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...